KNBIFKane Biotech Inc.

About Kane Biotech Inc. (KNBIF)

Kane Biotech Inc. (KNBIF) is a Biotechnology company headquartered in Winnipeg, MB, Canada whose shares trade over-the-counter on the OTCQB tier.

We are a Canadian-based technology company engaged in the development and commercialization of products that prevent and remove microbial biofilms.

Products and services

In 2023, the Kane Biotech announced the launch of its newly rebranded revyve™ Antimicrobial Wound Gel in its wound care line. revyve™ is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations. It is also indicated for management of minor skin scrapes, minor cuts, minor lacerations, minor burns (1st degree burns) and abrasions for adult populations. The Company also sells shampoo, shampoo bar and scalp detoxifier products under the DermaKB™ brand in its skin care line. These products are formulated to provide an effective cleansing of the scalp and to help support the reduction of skin irritation and other symptoms associated with common skin conditions. Both the revyve™ and DermaKB™ products contain Kane Biotech’s proprietary patented coactiv+™ technology.

KNBIF key facts

Ticker symbol

KNBIF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Winnipeg, MB, Canada

Country of incorporation

CA

Year of incorporation

2001

Employees

19

Estimated market cap

$10.83M (as of Apr 11, 2025)

Shares outstanding

154,771,567

Reporting standard

International Reporting: TSX Venture Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Quarterly Report (Sep 30, 2024)

Kane Biotech Inc. leadership

• Robert Huizinga — Officer
• Marc Edwards — President, CEO
• Ray Dupuis — CFO, Company Secretary
• Lori Christofalos — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with K